Depomed has announced a new launch of Lazanda fentanyl nasal spray in the US for the management of breakthrough pain in cancer patients who get inadequate relief from opioids. The company acquired the product from Archimedes in July 2013. Depomed is offering a new patient support system for the drug that is “designed to streamline patient access” and that includes “reimbursement assistance with co-pay support” and “benefit verification and prior authorization facilitation.”
Depomed President and CEO Jim Schoeneck said, “We recognize that patients with breakthrough cancer pain face many challenges, including reimbursement and access issues. With the new Signature Support Program, patients can take advantage of a variety of coordinated resources to make sure the process of starting on Lazanda is as simple as possible.”
Lazanda was approved by the FDA in June 2011 and was launched by Archimedes in October of that year. In Europe, the product is known as PecFent and has been marketed by Archimedes since 2010.
Read the Depomed press release.
